KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Other Operating Expenses (2019 - 2025)

Castle Biosciences (CSTL) has disclosed Other Operating Expenses for 7 consecutive years, with $20.6 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses changed 0.33% to $20.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $105.9 million through Dec 2025, up 48.46% year-over-year, with the annual reading at $105.9 million for FY2025, 48.46% up from the prior year.
  • Other Operating Expenses hit $20.6 million in Q4 2025 for Castle Biosciences, down from $21.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $44.7 million in Q1 2025 to a low of -$10.6 million in Q2 2022.
  • Historically, Other Operating Expenses has averaged $14.1 million across 5 years, with a median of $13.6 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: surged 1397.35% in 2021 and later crashed 368.53% in 2022.
  • Year by year, Other Operating Expenses stood at $5.6 million in 2021, then surged by 104.01% to $11.4 million in 2022, then increased by 28.5% to $14.7 million in 2023, then surged by 39.67% to $20.5 million in 2024, then grew by 0.33% to $20.6 million in 2025.
  • Business Quant data shows Other Operating Expenses for CSTL at $20.6 million in Q4 2025, $21.0 million in Q3 2025, and $19.6 million in Q2 2025.